KEGG   DISEASE: ワルファリンレジスタンス
エントリ  
H01205                                                             
名称    
ワルファリンレジスタンス
概要    
Warfarin is widely prescribed anticoagulant for the prevention of thromboembolic diseases. However, its use is made difficult by the wide interindividual variation in dose required to achieve a therapeutic effect, the narrow therapeutic range, and the risk of serious bleeding. Warfarin dose requirement is influenced by factors such as intake of vitamin K, ethnicity, age, gender, and genetic factors. Warfarin acts through interference with the recycling of vitamin K in the liver. It has been reported that mutations in VKORC1, CYP2C9, and GGCX cause warfarin resistance.
カテゴリ  
先天性代謝異常症
パスウェイ 
hsa00130  Ubiquinone and other terpenoid-quinone biosynthesis
hsa00830  Retinol metabolism
hsa00980  Metabolism of xenobiotics by cytochrome P450
病因遺伝子 
VKORC1 [HSA:79001] [KO:K05357]
CYP2A6 [HSA:1548] [KO:K17683]
CYP2C9 [HSA:1559] [KO:K17719]
GGCX [HSA:2677] [KO:K10106]
リンク   
MeSH: C563039
OMIM: 122700
文献    
  著者
Osinbowale O, Al Malki M, Schade A, Bartholomew JR
  タイトル
An algorithm for managing warfarin resistance.
  雑誌
Cleve Clin J Med 76:724-30 (2009)
DOI:10.3949/ccjm.76a.09062
文献    
  著者
Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P
  タイトル
Association of warfarin dose with genes involved in its action and metabolism.
  雑誌
Hum Genet 121:23-34 (2007)
DOI:10.1007/s00439-006-0260-8
文献    
  著者
Pelkonen O, Rautio A, Raunio H, Pasanen M
  タイトル
CYP2A6: a human coumarin 7-hydroxylase.
  雑誌
Toxicology 144:139-47 (2000)
DOI:10.1016/S0300-483X(99)00200-0
LinkDB    

» English version

DBGET integrated database retrieval system